Lipid Nanoparticle Patent Landscape

Lipid Nanoparticle Patent Landscape Outlook

The LNP patent landscape features more than 2,500 patents covering a wide spectrum of innovations in this field.

Lipid Nanoparticle Patent Landscape: Key Takeaways

Growing Interest in Lipid Nanoparticle Formulations

• It is worth noting that (nearly 40%) drug formulations are poorly soluble in aqueous media, limiting drug delivery efficiency, thereby increasing demand for advanced formulation technologies like lipid nanoparticles (LNPs).
• Presently, researchers are evaluating approximately 70% of BCS class II drugs across different clinical stages, providing a wide opportunity for the use of LNPs in improving the bioavailability of these drugs.
• Notably, around 45% of the USFDA approved nanoparticle drugs are lipid-based formulations.

Market Introduction

Over the years, various technological advances and discoveries have significantly changed the practice of medicine. One such advancement that came into light was the development of lipid nanoparticle-based drug delivery systems, which have demonstrated remarkable therapeutic potential while being largely devoid of the severe toxicity issues commonly associated with conventional pharmacological interventions.

Low drug solubility and its corresponding impact on bioavailability are a primary cause of concern with several marketed as well as clinical stage drugs. It is worth noting that close to 90% of drug candidates under development, are poorly soluble in aqueous media, limiting drug delivery efficiency. As a result, the industry is actively seeking innovative drug delivery methods to mitigate this challenge.

Amongst the various approaches to enhance bioavailability of therapeutic interventions, lipid nanoparticles (LNPs) and other lipid-based excipients have gained sufficient attention from drug developers, owing to their ability to act as drug carriers for complex formulations. In fact, researchers and pharmaceutical companies are actively advancing LNP-based therapeutic and vaccine candidates across a wide spectrum of disease indications, including infectious diseases, rare genetic disorders, oncology, and cardiovascular conditions.

Presently, several studies are underway to refine key aspects of LNP production, including next-generation microfluidic mixing devices, advanced analytical tools for particle characterization and improved payload integrity. Given the extensive research activity, the lipid nanoparticle IP landscape related to drug delivery has also grown over time. Therefore, it is important to keep track of both pockets of innovation and key areas of improvement for stakeholders to remain competitive in this upcoming field of healthcare.

LNP Patent Landscape Key Insights

What are Some Key Technological Developments Related to Lipid Nanoparticles?

• Advances in LNP Technologies: The lipid nanoparticle domain is rapidly expanding, with technological breakthroughs. Recently, an AI-driven platform from University of Toronto’s LUMI-lab has accelerated tissue-specific LNP design for extrahepatic targets like the brain and immune cells, advancing personalized RNA therapies. Moreover, the researchers at University of Pennsylvania developed nitro-oleic acid-modified LNPs that enable safer and longer-lasting gene expression in mice by inhibiting inflammatory pathways.
• Scalable Manufacturing Breakthroughs: New systems like microfluidic platforms enable small-batch personalization and mass production, addressing supply chain limitations for commercial production of lipid nanoparticles.

Industry Experts on Lipid Nanoparticles for Drug Delivery

Experts believe that using lipid nanoparticles for drug delivery can be a game changer for healthcare sector.

Jessica Madigan (Director Business Development - Nucleic Acid Modalities, BIOVECTRA, (Acquired by Agilent)), stated that, “As more lipid nanoparticle formulated products reach clinical and commercial stages, outsourcing of LNP formulation is likely to increase. This is because lipid nanoparticle formulation is a relatively efficient process. Once a reliable method is established, it is not overly complex. Pharmaceutical companies often prefer to handle complex and proprietary processes in-house, while simpler, more transferable processes like LNP formulation are often outsourced to enhance efficiency.”

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study on lipid nanoparticle IP landscape. The report includes transcripts of the following discussions:

• Business Unit Director Nanomedicines - Research & Development, Large Company, Belgium
• Sales Representative and Business Development Associate, Mid-sized Company, Spain

Apart from this the report also includes transcripts of the following third-party discussions:

• Bioengineering Professor, Very Large Organization, US
• Formulation and Manufacturing Experts, Very Large Company, Germany
• Head of Intracellular Drug Delivery Centre, Large Organization, US

Lipid Nanoparticle Patent Trends

• Popular / Relevant LNP Prior Art Search Expressions: An examination of intellectual property literature assists in the shortlisting of key words and important phrases used to describe lipid nanoparticles in drug delivery. In fact, it also provides details on the historical use of the terms across different IP filings, key affiliated terms (used to identify other relevant IP search terms and establish relationships between prior art search expressions), and other related trends.
• Patent Valuation: Notably, competitive benchmarking and valuation to determine the relative value of each IP document, facilitates the identification of high impact patents with significant potential for partnerships and investments.

• Patentability and Freedom to Operate: Researchers are identifying relevant areas of innovation in LNP domain by analyzing published IP documents (representative of unique patent families) that define the uniqueness of a patent. This further helps to assess the scope of patentability in this domain, and pinpoint jurisdictions wherein new and / or modified claims may be filed without infringing on existing IP.
• Analysis of Patent Applications: Presently, over 1,200 patent applications have been filed in the lipid nanoparticle domain. Notably, majority of the applications were filed in the year 2024.

• Lipid Nanoparticle Granted Patents: A meaningful classification system, segregating granted patents into relevant categories helps to develop a detailed perspective on the diversity of intellectual capital (having marketing exclusivity). This helps the innovators in this domain to assess the likelihood for entering into promising research areas. Notably, over 570 patents describing innovations in lipid nanoparticles, associated technologies, and their applications in drug delivery have been approved since 1998.
• Pockets of Innovation and White Spaces: LNP CPC analysis of the most frequently used CPC symbols in the dataset revealed that primary focus of innovation in the contemporary scenario is on the preparation method for lipid nanoparticles used in drug delivery. Moreover, white spaces demonstrate several other promising areas of innovation within the lipid nanoparticle domain; one such innovation area with high patentability includes stabilization methods of LNPs and liposomes.

Scope of Lipid Nanoparticle Patent Landscape Report

Frequently Asked Questions